Evogene Market Cap ($2.24 Million)
Market Cap & Net Worth: Evogene (EVGN)
Evogene market cap. Evogene (TA:EVGN) has a market capitalization of $2.24 Million (ILA836.95 Million) as of November 6, 2026. Listed on the TA stock exchange, this Israel-based company holds position #29877 globally and #433 in its home market, demonstrating a -17.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evogene's stock price ILA96.00 by its total outstanding shares 8718193 (8.72 Million). Also see Evogene cash flow conversion for how efficiently the company converts equity into cash flow.
Evogene Market Cap History (2015–2026)
Evogene market cap history from 2015 to 2026. Data shows change from $727.37 Million to $2.24 Million (-40.86% CAGR). Check Evogene stock quote for real-time trading data and today's change.
Evogene Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evogene's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Evogene net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.00x
Evogene's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $727.37 Million | $11.13 Million | -$17.21 Million | 65.36x | N/A |
| 2016 | $458.11 Million | $6.54 Million | -$19.59 Million | 70.05x | N/A |
| 2017 | $264.12 Million | $3.38 Million | -$20.84 Million | 78.12x | N/A |
| 2018 | $181.84 Million | $1.75 Million | -$20.76 Million | 104.09x | N/A |
| 2019 | $122.85 Million | $753.00K | -$19.11 Million | 163.15x | N/A |
| 2020 | $360.88 Million | $1.04 Million | -$26.21 Million | 347.00x | N/A |
| 2021 | $125.63 Million | $930.00K | -$30.45 Million | 135.09x | N/A |
| 2022 | $52.24 Million | $1.68 Million | -$29.84 Million | 31.19x | N/A |
| 2023 | $70.07 Million | $5.64 Million | -$23.88 Million | 12.42x | N/A |
| 2024 | $17.02 Million | $8.51 Million | -$16.48 Million | 2.00x | N/A |
Competitor Companies of EVGN by Market Capitalization
Companies near Evogene in the global market cap rankings as of November 6, 2026. Also see EVGN total assets for a full breakdown of the balance sheet.
Key companies related to Evogene by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Evogene (2015–2026)
Market capitalization of Evogene from 2015 to today. Between 2015 and today, Evogene's market cap moved from $727.37 Million to $ 2.24 Million, with a yearly change of -40.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA2.24 Million | -67.94% |
| 2025 | ILA7.00 Million | -58.87% |
| 2024 | ILA17.02 Million | -75.72% |
| 2023 | ILA70.07 Million | +34.14% |
| 2022 | ILA52.24 Million | -58.42% |
| 2021 | ILA125.63 Million | -65.19% |
| 2020 | ILA360.88 Million | +193.76% |
| 2019 | ILA122.85 Million | -32.44% |
| 2018 | ILA181.84 Million | -31.15% |
| 2017 | ILA264.12 Million | -42.35% |
| 2016 | ILA458.11 Million | -37.02% |
| 2015 | ILA727.37 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Evogene was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.24 Million USD |
| MoneyControl | $2.24 Million USD |
| MarketWatch | $2.24 Million USD |
| marketcap.company | $2.24 Million USD |
| Reuters | $2.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more